Catalyst Wire Dossier Catalyst Wire Dossier

Glecaprevir/pibrentasvir (Mavyret)

glecaprevir/pibrentasvir · AbbVie
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Glecaprevir/pibrentasvir (Mavyret), covering 2024-07-11 to 2024-12-03. Get the full timeline:

Most recent: Clinical Trial Update: QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir [Phase 4]

See pricing